Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Antifungal therapeutic drug monitoring: established and emerging indications.

Literature DB >> 18955533

Antifungal therapeutic drug monitoring: established and emerging indications.

David Andes¹, Andres Pascual, Oscar Marchetti.

Abstract

Mesh：

Substances：
Antifungal Agents

Year: 2008 PMID： 18955533 PMCID： PMC2612175 DOI： 10.1128/AAC.00705-08

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

× No keyword cloud information.

96 in total

1. Effect of a cola beverage on the bioavailability of itraconazole in the presence of H2 blockers.

Authors: D Lange; J H Pavao; J Wu; M Klausner
Journal: J Clin Pharmacol Date: 1997-06 Impact factor: 3.126

2. Enhanced bioavailability of itraconazole in hydroxypropyl-beta-cyclodextrin solution versus capsules in healthy volunteers.

Authors: J A Barone; B L Moskovitz; J Guarnieri; A E Hassell; J L Colaizzi; R H Bierman; L Jessen
Journal: Antimicrob Agents Chemother Date: 1998-07 Impact factor: 5.191

3. Influence of an acidic beverage (Coca-Cola) on the absorption of itraconazole.

Authors: S Jaruratanasirikul; A Kleepkaew
Journal: Eur J Clin Pharmacol Date: 1997 Impact factor: 2.953

Review 4. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards.

Authors: J H Rex; M A Pfaller; J N Galgiani; M S Bartlett; A Espinel-Ingroff; M A Ghannoum; M Lancaster; F C Odds; M G Rinaldi; T J Walsh; A L Barry
Journal: Clin Infect Dis Date: 1997-02 Impact factor: 9.079

5. Effect of food on the pharmacokinetics of a new hydroxypropyl-beta-cyclodextrin formulation of itraconazole.

Authors: V J Van de Velde; A P Van Peer; J J Heykants; R J Woestenborghs; P Van Rooy; K L De Beule; G F Cauwenbergh
Journal: Pharmacotherapy Date: 1996 May-Jun Impact factor: 4.705

Review 6. Therapeutic drug monitoring of systemic antifungal therapy.

Authors: K K Summers; T C Hardin; S J Gore; J R Graybill
Journal: J Antimicrob Chemother Date: 1997-12 Impact factor: 5.790

7. Itraconazole solution: higher serum drug concentrations and better clinical response rates than the capsule formulation in acquired immunodeficiency syndrome patients with candidosis.

Authors: J D Cartledge; J Midgely; B G Gazzard
Journal: J Clin Pathol Date: 1997-06 Impact factor: 3.411

Review 8. Itraconazole in cyclodextrin solution.

Authors: D A Stevens
Journal: Pharmacotherapy Date: 1999-05 Impact factor: 4.705

9. Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model.

Authors: D Andes; M van Ogtrop
Journal: Antimicrob Agents Chemother Date: 1999-09 Impact factor: 5.191

Review 10. Optimisation of itraconazole therapy using target drug concentrations.

Authors: J M Poirier; G Cheymol
Journal: Clin Pharmacokinet Date: 1998-12 Impact factor: 6.447

140 in total

1. Ultra-performance liquid chromatography mass spectrometry and sensitive bioassay methods for quantification of posaconazole plasma concentrations after oral dosing.

Authors: Bertrand Rochat; Andres Pascual; Benoît Pesse; Frédéric Lamoth; Dominique Sanglard; Laurent A Decosterd; Jacques Bille; Oscar Marchetti
Journal: Antimicrob Agents Chemother Date: 2010-10-04 Impact factor: 5.191

Review 2. Triazole antifungal agents in invasive fungal infections: a comparative review.

Authors: Cornelia Lass-Flörl
Journal: Drugs Date: 2011-12-24 Impact factor: 9.546

3. Clinical pharmacodynamics and pharmacokinetics of the antifungal extended-spectrum triazole posaconazole: an overview.

Authors: Hans-Peter Lipp
Journal: Br J Clin Pharmacol Date: 2010-10 Impact factor: 4.335

4. Multiplex ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-N-oxide, anidulafungin, and caspofungin.

Authors: Laurent Arthur Decosterd; Bertrand Rochat; Benoît Pesse; Thomas Mercier; Frédéric Tissot; Nicolas Widmer; Jacques Bille; Thierry Calandra; Boris Zanolari; Oscar Marchetti
Journal: Antimicrob Agents Chemother Date: 2010-09-20 Impact factor: 5.191